ArticlemAbs2014
IgG4 can induce an M2-like phenotype in human monocyte-derived macrophages through FcγRI.
Article in mAbs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Review
- Tumors in the setting of dupilumab use: A review of the literature.The World Allergy Organization journal · 2025Review
- Fc-Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies.Journal for immunotherapy of cancer · 2024Article
- Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress.Frontiers in pharmacology · 2024Review
- Role of Microglial Cells in the Pathophysiology of MS: Synergistic or Antagonistic?International journal of molecular sciences · 2023Review
- Review
- Improving Antibody Therapeutics by Manipulating the Fc Domain: Immunological and Structural Considerations.Annual review of biomedical engineering · 2022Review
- Review
- CGRP-Mediated Prolactin Upregulation: a Possible Pathomechanism in IgG4-Related Disease.Inflammation · 2021Article
- Functional effects of immune complexes formed between pembrolizumab and patient-generated anti-drug antibodies.Cancer immunology, immunotherapy : CII · 2020Article
- Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know.Journal of experimental & clinical cancer research : CR · 2020Review
- The Role of IgG4 in the Fine Tuning of Tolerance in IgE-Mediated Allergy and Cancer.International journal of molecular sciences · 2020Review
- Pulmonary Eosinophilic Granulomatosis with Polyangiitis Has IgG4 Plasma Cells and Immunoregulatory Features.The American journal of pathology · 2020Article
- The Diverse Functions of the Ubiquitous Fcγ Receptors and Their Unique Constituent, FcRγ Subunit.Pathogens (Basel, Switzerland) · 2020Review
- IgG4 drives M2a macrophages to a regulatory M2b-like phenotype: potential implication in immune tolerance.Allergy · 2019Article
- High level of IgG4 as a biomarker for a new subset of inflammatory bowel disease.Scientific reports · 2018Article
- The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions.Cancer immunology, immunotherapy : CII · 2018Article
- Pathological manifestations in lymphatic filariasis correlate with lack of inhibitory properties of IgG4 antibodies on IgE-activated granulocytes.PLoS neglected tropical diseases · 2017Article
- Modulation of Microglial Cell Fcγ Receptor Expression Following Viral Brain Infection.Scientific reports · 2017Article
- Characterization of NF-κB Reporter U937 Cells and Their Application for the Detection of Inflammatory Immune-Complexes.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibodies evoke cellular responses through the binding of their Fc region to Fc receptors, most of which contain immunoreceptor tyrosine-based activation motif domains and are thus considered "activating." However, there is a growing appreciation of these receptors for their ability to deliver an inhibitory signal as well. We previously described one such phenomenon whereby interferon (IFN)γ signaling is inhibited by immune complex signaling through FcγRI. To understand the implications of this in the context of therapeutic antibodies, we assessed individual IgG subclasses to determine their ability to deliver this anti-inflammatory signal in monocyte-derived macrophages. Like IgG1, we found that IgG4 is fully capable of inhibiting IFNγ-mediated events. In addition, F(ab')2 fragments that interfere with FcγRI signaling reversed this effect. For mAbs developed with either an IgG1 or an IgG4 constant region for indications where inflammation is undesirable, further examination of a potential Fc-dependent contribution to their mechanism of action is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.